ES2297024T3 - Compuestos utiles para el diagnostico y seguimiento de enfermedades asociadas con la formacion de fibrilas proteicas amiloides. - Google Patents

Compuestos utiles para el diagnostico y seguimiento de enfermedades asociadas con la formacion de fibrilas proteicas amiloides. Download PDF

Info

Publication number
ES2297024T3
ES2297024T3 ES02785448T ES02785448T ES2297024T3 ES 2297024 T3 ES2297024 T3 ES 2297024T3 ES 02785448 T ES02785448 T ES 02785448T ES 02785448 T ES02785448 T ES 02785448T ES 2297024 T3 ES2297024 T3 ES 2297024T3
Authority
ES
Spain
Prior art keywords
quad
hydroxyquinoline
chloro
complex
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02785448T
Other languages
English (en)
Spanish (es)
Inventor
Jorge Setoain Quinquer
Carlos Piera Pena
Isabel Ramirez De Arellano Serna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CETIR CT MEDIC S A
CETIR CENTRE MEDIC SA
Catalana de Dispensacion SA
Barnatron SA
Original Assignee
CETIR CT MEDIC S A
CETIR CENTRE MEDIC SA
Catalana de Dispensacion SA
Barnatron SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CETIR CT MEDIC S A, CETIR CENTRE MEDIC SA, Catalana de Dispensacion SA, Barnatron SA filed Critical CETIR CT MEDIC S A
Application granted granted Critical
Publication of ES2297024T3 publication Critical patent/ES2297024T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/30—Metal salts; Chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES02785448T 2002-11-18 2002-11-18 Compuestos utiles para el diagnostico y seguimiento de enfermedades asociadas con la formacion de fibrilas proteicas amiloides. Expired - Lifetime ES2297024T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000537 WO2004045651A1 (es) 2002-11-18 2002-11-18 Compuestos utiles para el diagnostico y seguimiento de enfermedades relacionadas con la formación de fibrilas proteicas amiloides

Publications (1)

Publication Number Publication Date
ES2297024T3 true ES2297024T3 (es) 2008-05-01

Family

ID=32319763

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02785448T Expired - Lifetime ES2297024T3 (es) 2002-11-18 2002-11-18 Compuestos utiles para el diagnostico y seguimiento de enfermedades asociadas con la formacion de fibrilas proteicas amiloides.

Country Status (8)

Country Link
US (1) US20080063599A1 (https=)
EP (1) EP1563852B1 (https=)
JP (1) JP2006514928A (https=)
AU (1) AU2002350751C1 (https=)
CA (1) CA2505506C (https=)
DE (1) DE60223729T2 (https=)
ES (1) ES2297024T3 (https=)
WO (1) WO2004045651A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005216949B2 (en) 2004-02-24 2011-09-22 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
JP5603074B2 (ja) 2006-09-08 2014-10-08 ピラマル イメージング ソシエテ アノニム １８ｆ標識物質のための化合物と方法
CA2978149C (en) 2008-03-21 2019-02-12 The General Hospital Corporation Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders
US10781178B2 (en) 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
CN110759952B (zh) * 2019-09-27 2021-04-20 广西师范大学 基于8-甲氧基喹啉构筑的钴配合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279887A (en) * 1978-11-29 1981-07-21 Medi-Physics, Inc. Amides useful as brain imaging agents
US4360509A (en) * 1979-12-19 1982-11-23 Byk-Mallinckrodt Cil B.V. Vivo radioassay process
US5045303A (en) * 1985-05-17 1991-09-03 Neorx Corporation Radiohalogenated small molecules for protein labeling
AU720643B2 (en) * 1996-08-13 2000-06-08 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
JP3772506B2 (ja) * 1998-01-19 2006-05-10 三菱化学株式会社 キノリノール誘導体、その金属錯体およびそれを用いた有機電界発光素子
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6589504B1 (en) * 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions

Also Published As

Publication number Publication date
DE60223729T2 (de) 2008-10-30
AU2002350751B2 (en) 2006-04-06
AU2002350751C1 (en) 2006-11-16
AU2002350751A8 (en) 2004-06-15
CA2505506C (en) 2008-07-08
EP1563852A1 (en) 2005-08-17
AU2002350751A1 (en) 2004-06-15
DE60223729D1 (de) 2008-01-03
WO2004045651A1 (es) 2004-06-03
CA2505506A1 (en) 2004-06-03
US20080063599A1 (en) 2008-03-13
EP1563852B1 (en) 2007-11-21
JP2006514928A (ja) 2006-05-18

Similar Documents

Publication Publication Date Title
Wang et al. Development of a PET/SPECT agent for amyloid imaging in Alzheimer’s disease
Zhang et al. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain
Zhuang et al. IBOX (2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain
ES2427963T3 (es) Uso de derivados de tioflavina radiomarcados en formación de imágenes de amiloide para evaluación de las terapias antiamiloide
JP2008546804A (ja) 造影剤として用いるためのリガンドの放射性標識ペグ化
EP2218464A1 (en) Compounds for non-invasive measurement of aggregates of amyloid peptides
CN101355940B (zh) 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法
Serdons et al. Synthesis and evaluation of a 99mTc-BAT-phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid β
JP2024502341A (ja) デュアルモード放射性トレーサーおよびその療法
Nguyen et al. IBETA: A new aβ plaque positron emission tomography imaging agent for Alzheimer’s disease
Ono et al. 18F-labeled flavones for in vivo imaging of β-amyloid plaques in Alzheimer’s brains
ES2297024T3 (es) Compuestos utiles para el diagnostico y seguimiento de enfermedades asociadas con la formacion de fibrilas proteicas amiloides.
ES2393921T3 (es) Compuestos derivados de BENZOTIAZOL, composiciones y usos
EP2198040B1 (en) In vivo imaging of myelin
Chang et al. Synthesis and evaluation of benzothiophene derivatives as ligands for imaging β-amyloid plaques in Alzheimer's disease
EP3793619A1 (en) Styrylbenzothiazole derivatives and uses in imaging
Neumaier et al. Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease
ES2264259T3 (es) Agentes de obtencion de imagenes por spect (tomografia por emision de foton unico) para transportador de serotonina.
EA020612B1 (ru) ПРИМЕНЕНИЕ 7-ХЛОР-N,N,5-ТРИМЕТИЛ-4-ОКСО-3-ФЕНИЛ-3,5-ДИГИДРО-4Н-ПИРИДАЗИН[4,5-b]ИНДОЛ-1-АЦЕТАМИДА В КАЧЕСТВЕ БИОМАРКЕРА УРОВНЕЙ ПЕРИФЕРИЧЕСКОГО БЕНЗОДИАЗЕПИНОВОГО РЕЦЕПТОРА
WO2012017891A1 (ja) ピリジルベンゾフラン誘導体
Nguyen et al. [124I] BETA, a new beta-amyloid plaque PET imaging agent for Alzheimer's disease
HK40062845A (zh) Psma-結合劑及其用途
WO2011124713A1 (en) Labelled huprine derivatives and their use in medical imaging
CN108299287A (zh) 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物